Cancer survivors and their supporters demonstrated last month outside New York City Hall in a push for stricter rules regarding tobacco products, a posting on the American Cancer Society (ACS) website said.
Speculation that Republican Senate leaders will draft a health care bill that is hugely different than the measure that passed the House is "vastly overstated," Tom Miller, a resident fellow at the American Enterprise Institute, said.
Researchers in Boston are using a sophisticated new tool to figure out why up to half of colon cancer cases are missed, even when using colonoscopies that have significantly blunted the threat from this deadly disease.
Novartis said it will collaborate with IBM Watson Health on an initiative that will combine Novartis’ expertise in breast cancer with Watson’s data analytics and machine learning to advance cancer care and boost patient outcomes.
U.S. lawmakers are considering a legislative proposal that would reauthorize the Prescription Drug User Fee Act (PDUFA) and potentially drive innovation in the pharmaceutical industry and among regulators.
Patients suffering from triple negative breast cancer, a treatment-resistant form of the disease, have a new option in pembrolizumab, a drug manufactured by Merck that was previously FDA-authorized for other malignancies.
Tests of a drug that may help inhibit the growth of solid tumors in cancer patients have shown early signs of success, a paper presented at the American Society of Clinical Oncology meeting in Chicago said.
The National Cancers Survivors Day Foundation celebrated over 15.5 million cancer survivors alive on June 4, and the American Cancer Society wants to ensure they remain healthy by following six steps it posted on its website.
Horizon Pharma said in a release that a proposed generic version of its Pennsaid topical pain reliever has been sidelined in the U.S. by a court ruling upholding Horizon Pharma's patent infringement claim.
Bristol-Myers Squibb and Calithera Biosciences recently said they are expanding their current collaboration to evaluate Bristol-Myers Squibb's Opdivo (nivolumab) and Calithera's CB-839 in treating non-small cell lung cancer (NSCLC) and the skin cancer melanoma.